Seres Therapeutics Inc
MCRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$38.74M
Close$
$-3.63
200.3% downside
Current Fair Value
200.3% downsideOvervalued by 200.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $38.74 Million |
|---|---|
| Enterprise Value | $79.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.64 |
| Beta | 0.22 |
| Outstanding Shares | 9,644,704 |
Return
| Return on Equity | -65.05% |
|---|---|
| Return on Assets | -22.11% |
| Return on Invested Capital | -103.99% |
Valuation & Multiples
| P/E Ratio | -1.65 |
|---|---|
| PEG | 1.34 |
| Price to Sales | - |
| Price to Book Ratio | 1.21 |
| Enterprise Value to Revenue | 42.37 |
| Enterprise Value to EBIT | -0.94 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.71 |
| Debt to Equity | 1.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-2.18
Average shareholder expectationRevenue Estimate
$179,000
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
$6.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 9.6667▲ 747.27% |
|---|---|
| Total Calls | 11,100▼ 80.42% |
| Total Puts | 107,300▼ 13.75% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.90%▼ 0.17% |
|---|---|
| Total Invested | $18.19M▼ 11.09% |
| Investors Holding | 40▲ 4.00% |
ESG Score
No data
About Seres Therapeutics Inc
CEO: Eric Shaff